<DOC>
	<DOCNO>NCT00005835</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness melphalan buthionine sulfoximine follow bone marrow peripheral stem cell transplantation treat child resistant recurrent neuroblastoma .</brief_summary>
	<brief_title>N99-02 : Melphalan Buthionine Sulfoximine</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose melphalan combine buthionine sulfoximine follow autologous bone marrow peripheral blood stem cell support child resistant recurrent high-risk neuroblastoma . - Assess toxic effect regimen patient . - Determine pharmacokinetics regimen patient . - Determine response rate patient treat regimen . OUTLINE : This multicenter , dose-escalation study melphalan . Patients receive buthionine sulfoximine IV bolus 30 minute follow 72-hour continuous infusion begin day -4 ; melphalan IV 15 minute day -3 -2 ; autologous peripheral blood stem cell bone marrow IV 15-30 minute day 0 ; filgrastim ( G-CSF ) subcutaneously IV daily begin day 0 continue blood count recover . Cohorts 3-6 patient receive escalate dos melphalan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 84 day 2 month later complete and/or partial response . Patients continue therapy protocol follow start new therapy . All patient follow life delay toxic effect protocol therapy secondary malignancy . PROJECTED ACCRUAL : A total 30 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Buthionine Sulfoximine</mesh_term>
	<criteria>Patients relapse neuroblastoma must exhaust option treatment consider treatment study . Relapsed patient great 6 month since stem cell transplant enter study . Patients must stem cell collect store start treatment . Patients must double lumen central venous line place . Patients must adequate kidney liver function measure blood test test renal function ( creatinine clearance glomerular filtration rate ( GFR ) ) . Patients must normal heart lung function measure lack physical evidence clinical history difficulty breathe test cardiac function ( Echocardiogram MUGA evaluation ) . Patients must essentially normal neurological exam . Patients must one entire kidney radiation treatment dos . ( Xrays scan ok ) . Patients must recover effect prior treatment tumor . They radiation therapy brain . They know history current tumor find brain surround tissue . They history seizure . They history change test kidney function antibiotic use 6 month immediately enter study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>